Assessing the Impact of Pegylated-Interferon/Ribavirin Therapy Duration Versus Viral Response on Health-Related Quality of Life (Qol) Outcomes In Chronic Hepatitis C Virus (Hcv) Patients, Using Multivariate Mixed-Effects Modeling
Abstract
Authors
P Thilakarathne S Van Sanden J Diels A Mehnert